Compared to Estimates, Clorox (CLX) Q4 Earnings: A Look at Key Metrics

Clorox (CLX) reported strong Q4 2025 earnings, with revenue of $1.99 billion (+4.5% YoY) and EPS of $2.87, significantly surpassing analyst estimates by 3.04% and 28.12% respectively. The company saw robust organic revenue growth in its Health and Wellness (14%) and Household (7%) segments, contributing to an overall 8% organic sales growth. Despite these beats, CLX shares have underperformed the S&P 500 over the past month, and the stock currently carries a Zacks Rank #5 (Strong Sell), indicating potential near-term underperformance.

Analysis

Clorox (CLX) reported a robust fourth quarter for fiscal year 2025, significantly outperforming analyst expectations on both revenue and earnings. Total revenue reached $1.99 billion, a 4.5% year-over-year increase and a 3.04% surprise above the consensus estimate. The earnings per share (EPS) of $2.87 represented a particularly strong beat, coming in 28.12% higher than the $2.24 consensus. This performance was driven by exceptional strength in the Health and Wellness segment, which saw organic revenue growth of 14%—more than double the 6.3% estimate—and a 13.7% year-over-year increase in net revenue. The Household segment also contributed positively with 7% organic growth, surpassing the 4.6% estimate. However, this strength was partially offset by weaknesses elsewhere; the International segment's organic growth of 1% missed estimates of 2.4%, and the Lifestyle segment's 3% growth was well below the 6.3% forecast. Furthermore, a pre-tax loss of $56 million in the 'Corporate and Other' category was more than double the anticipated loss. Despite the strong headline numbers, the stock has underperformed the S&P 500 over the past month (+1.2% vs +2.7%), and the article highlights a Zacks Rank #5 (Strong Sell), indicating a bearish near-term outlook that contrasts sharply with the reported quarterly results.

Key Decisions for Investors

• Investors should recognize the significant EPS beat but must scrutinize the underlying weakness in the International and Lifestyle segments, which could signal challenges to diversified growth.
• The stark contrast between the strong earnings report and the stock's recent market underperformance, combined with a 'Strong Sell' rating, warrants caution and suggests the market may be pricing in future headwinds not captured in these historical results.
• It is prudent to monitor forthcoming margin performance, particularly given the larger-than-expected loss from the 'Corporate and Other' segment, which could offset the profitability gains seen in the Health and Wellness division.